ATYR - NASDAQ
aTyr Pharma, Inc.
$0.55
-4.9%aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
At a Glance
Live SnapshotaTyr Pharma, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
aTyr Pharma, Inc. Cash Flow Statement
ATYR • NASDAQ
| aTyr Pharma, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-74.1M | -64M | -50.4M | -45.3M | -33.8M | -16.2M | -23.6M | -34.5M | -48.2M | -57.9M | -48M | -24.4M | -20M | -17.6M | |
1.6M | 1.5M | 2.7M | 1.7M | 1.3M | 1.3M | 1.4M | 746K | 713K | 900K | 869K | 829K | 714K | 540K | |
5M | 3M | 2.6M | 2.2M | 1.6M | 1.5M | 1.8M | 0.0 | 0.0 | 0.0 | 4.9M | 1.8M | 155K | 0.0 | |
-1.9M | -2.7M | -3.2M | 441K | 363K | 453K | 235K | 7.7M | 10.8M | 7.2M | 2.2M | 156K | -15K | 4.9M | |
7.5M | -6.9M | 15M | -833K | -2.6M | -2.3M | 206K | -1.4M | -1.7M | -1.4M | 3.3M | -1.3M | 1.8M | 787K | |
-62M | -69.1M | -33.2M | -41.9M | -33.1M | -15.3M | -20M | -31.1M | -42.4M | -52.9M | -36.8M | -22.8M | -17.3M | -11.4M | |
INVESTING ACTIVITIES | ||||||||||||||
-77K | -65K | -4.2M | -1.6M | -192K | -202K | -79K | -594K | -1.3M | -600K | -664K | -249K | -644K | -598K | |
(12K) | (7K) | (0.0) | (0.0) | (50K) | (18K) | (51K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-93.4M | -69.1M | -107M | -42.1M | -126.5M | -21.1M | -40.6M | -40.3M | -77.7M | -28.1M | -109.4M | -5.4M | (0.0) | (0.0) | |
86.6M | 86.4M | 91.1M | 90.8M | 35.1M | 28.2M | 45.6M | 78.1M | 51.3M | 62.2M | 38.1M | 3.4M | 0.0 | 0.0 | |
1.9M | 0.0 | 15K | 179K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-5.1M | (17.2M) | -20.1M | (47.2M) | -91.6M | (6.9M) | (4.9M) | (37.2M) | -27.6M | (33.5M) | -72M | -2.2M | -644K | -598K | |
FINANCING ACTIVITIES | ||||||||||||||
66.6M | 40.3M | 66.5M | 5.5M | 110M | 25.2M | 9.3M | 379K | 42.5M | 0.0 | 76.9M | 0.0 | 0.0 | 4K | |
-539K | -497K | -394K | -66K | 0.0 | -9.1M | -8M | -4.7M | 9.9M | 4.5M | -5.2M | 3.4M | 12M | 1.7M | |
0.0 | 100K | 105K | 45K | 73K | 10K | 13K | 50K | 361K | 163K | 0.0 | -927K | 77K | 0.0 | |
66M | 39.9M | 66.2M | 5.5M | 110M | 16.1M | 1.3M | -4.2M | 52.7M | 4.7M | 147.9M | 2.5M | 50.7M | 1.7M | |
CASH FLOW SUMMARY | ||||||||||||||
-1M | -12M | 12.9M | 10.8M | -14.6M | 7.7M | -13.8M | 1.9M | -17.3M | -14.6M | 39.1M | -22.6M | 32.8M | 0.0 | |
14M | 26M | 13.1M | 2.3M | 17M | 9.2M | 23M | 21.1M | 38.4M | 53M | 13.9M | 36.5M | 3.7M | 0.0 | |
13M | 14M | 26M | 13.1M | 2.3M | 17M | 9.2M | 23M | 21.1M | 38.4M | 53M | 13.9M | 36.5M | 3.7M | |
-62.1M | -69.2M | -37.4M | -43.5M | -33.3M | -15.5M | -20.1M | -31.7M | -43.7M | -53.5M | -37.5M | -23.1M | -18M | -12M |
SEC Filings
ATYR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ATYR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.